📉Lower LDL-C for longer is better. The NLA’s new guidance simplifies LDL-C management for adults — helping clinicians & patients improve evidence-based measurement and treatment of LDL-C. Read the guidelines & recommendations: lipidjournal.com/article/S1933-…. Beth Jackson Christie Ballantyne

The GLP1 discontinuation rate in the real world is alarmingly high. 64% at 1 year and 84% at 2 years in those without diabetes‼️ Risk factors of discontinuation include lower income, older age, lower weight loss, cost, among others. 🔬Further research into the predictors of

Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial diabetesjournals.org/care/article-a… Diabetes Care, a research journal of the ADA 🌟

Realigning #diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies thelancet.com/journals/landi… #T1D #T2D #olderadults #FREE to read with registration (also FREE) #ADA2025

At #ADASciSessions, Shah et al. report results of an RCT of semaglutide in patients with T1DM and obesity. Read the full report: eviden.cc/43YIrGt Dr. Halis Kaan Akturk American Diabetes Association - DiabetesPro

📌 Type 2 #diabetes in 2025: are we doing it right? 🔎 Diagnosis: still under-recognized 💊 Treatment: more options, more complexity ❤️ #CV & #renal risk: front and center 🧠 Individualized care is not optional 📄 JAMA 2025: A Review doi.org/10.1001/jama.2…

INVITED REVIEW Should anti-Müllerian hormone be a diagnosis criterion for polycystic ovary syndrome? An in-depth review of pros and cons by Emídio Vale-Fernandes et al EJE Volume 192, Issue 4, April 2025 Open access 👉 doi.org/10.1093/ejendo… #PCOS #PCOM #infertility

🧬 Early-onset #T2D (≤40y) is rising fast—and it hits harder 🔹 Earlier complications 🔹 Delayed diagnosis & treatment 🔹 Greater lifetime burden 🔹 A public health + precision care problem 📄 The Lancet 2025 🔗 doi.org/10.1016/S0140-… #EndoTwitter #Diabetes #GlobalHealth

📌 #LDL-C is not the whole story. 🔬 #ApoB-100 shape—not just quantity—may drive plaque risk 🧱 Particle retention 🧬 Aggregation in arterial wall 🔜 We may treat how apoB behaves, not just how much there is 📄 Curr Opin Lipidol 2025 🔗 doi.org/10.1097/MOL.00… #EndoTwitter

Just published commentary shows how expanding definitions of diseases such as #hypertension, gestational #diabetes, #osteoporosis, attention-deficit/hyperactivity disorder & social #anxiety disorder can result in harmful #medicalization & inefficient resource use.

Pelacarsen is the first potential medical therapy for targeting Lp(a) directly Our new review Journal of Clinical Lipidology describes its mechanism of action and evidence so far: lipidjournal.com/article/S1933-… Archna Bajaj UC San Diego Cardiology UC San Diego Cardiology Fellows National Lipid Association ASPC Family Heart Foundation

📕Approach to Lipid Management in the Patient With Diabetes 📍 El metabolismo lipídico alterado es un contribuyente importante al riesgo de #ECV ateroesclerótica en la diabetes academic.oup.com/jcem/article/1… LipidoSEEN Área Diabetes SEEN

🍽️ #Nutritional support in #neuroendocrine tumors: often forgotten, always needed 🔎 ENETS calls for early screening & tailored interventions 💊 Address Pancreatic Exocrine Insufficiency, micronutrient loss, surgery, diarrhea 📄 JNE 2025 🔗 doi.org/10.1111/jne.70…

🩺 American College of Cardiology 2025 Expert Consensus: Treating #obesity is CV prevention 🔹 Prioritize weight loss in #ASCVD, #HFpEF, #T2D 🔹 Use GLP-1RA or TZP when indicated 🔹 Base treatment on CV risk, not just BMI 🔹 Ensure equitable access 📄 JACC Journals 2025 🔗 doi.org/10.1016/j.jacc…

Our UK Non-functioning Pituitary Adenoma Consortium papers in this guideline Conservatively managed non-functioning pituitary macroadenomas doi.org/10.1093/ejendo… Natural history of non-functioning pituitary microadenomas doi.org/10.1093/ejendo…